Today's view of hereditary thrombophilia

Česká verzia

Authors: Jan Kvasnička ^1,2; Zuzana Kovářová-Kudrnová ¹; Zuzana Zenáhlíková ¹; Radka Brzežková ¹; Sylvie Šťastná ¹; Petra Bobčíková ¹; Tomáš Kvasnička ¹
Authors place of work: Trombotické centrum Ústavu klinické biochemie a laboratorní diagnostiky, Praha ¹; 1. interní klinika, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha ²
Published in the journal: Vnitř Lék 2022; 68(8): 488-492
Category: Main Topic
doi: https://doi.org/10.36290/vnl.2022.105

Summary

Venous thromboembolism (VTE) is still a serious medical problem with the non-decreasing incidence of new cases despite prophylaxis in risky situations. It is a multifactorial disease, in which the hereditary component is also significantly involved. The aim of the current research is to search for new polymorphisms that are involved in thrombogenesis in addition to classical thrombophilia (deficiency of natural coagulation inhibitors and FVL and FII prothrombin mutations). The article provides an overview of the results of already performed genome-wide association studies of VTE and their use for the calculation of the so-called polygenic risk score, which could be used for individualized prevention of VTE after standardization of the method.

Keywords:

thrombophilia – Venous thromboembolism – genome‑wide association studies – polygenic risk score – individualized prevention

Zdroje

1. Cohen AT, Agnelli G, Anderson FA et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-64.

2. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14.

3. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014;12(10):1580-90.

4. Bell EJ, Lutsey PL, Basu S et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med. 2016;129 339: e19-e26

5. Arnesen, CAL, Veres K, Horváth‑Puhó E et al. Estimated lifetime risk of venous thromboembolism in men and women in a Danish nationwide cohort: impact of competing risk of death. Eur J Epidemiol. 2022;37:195-203.

6. Heit JA, Ashrani A, Crusan DJ et al. Reasons for the persistent incidence of venous thromboembolism. Thromb Haemost 2017;117(2):390-400.

7. Lo Re V 3rd, Dutcher SK, Connolly JG et al. Association of COVID-19 vs influenza with risk of arterial and venous thrombotic events among hospitalized patients. JAMA 2022; 328(7):637-651.

8. Malas MB, Naazie IN, Elsayed N et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta‑analysis. EClinicalMedicine 2020;29:100639.

9. Hirnerová J, Karetová D, Malý R et al. Akutní žilní trombóza: současný stav prevence, diagnostiky a léčby (aktualizovaná verze 2020). Doporučený postup České angiologické společnosti. Available from: http://www.angiology.cz.

10. Rokyta R, Hutyra M, Jansa P. Doporučené postupy Evropské kardiologické společnosti (ESC) pro diagnostiku a léčbu akutní plicní embolie, verze 2019. Stručný přehled vypracovaný Českou kardiologickou společností. Cor Vasa. 2020;62:154-182.

11. Humbert M, Kovacs G, Hoeper MM et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; DOI:10.1093/eurheartj/ehac237.

12. Klok FA, Ageno W, Ay C et al. Optimal follow‑up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. Eur Heart J. 2022;43(3):183-189.

13. Kyrle PA, Kammer M, Eischer L et al. The long‑term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost. 2016;14(12):2402-2409.

14. Jiménez D, Díaz G, Marín E et al. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost. 2006;95(3):562-566.

15. Kearon C. Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated. J Thromb Thrombolysis. 2011;31(3):295-300.

16. Barco S, Corti M, Trinchero A et al. Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. J Thromb Haemost. 2017;15(7):1436-1442.

17. Rosendaal F. Venouds thrombosis: a multicausal disease. Lancet. 199;353:1167-1173.

18. Margaglione M, Grandone E. Population genetics of venous thromboembolism. A narrative review. Thromb Haemost. 2011;105(2):221-31.

19. Zöller B, Li X, Ohlsson H et al. Family history of venous thromboembolism as a risk factor and genetic research tool. Thromb Haemost. 2015;114(5):890-900.

20. Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost. 2015;114(5):885-9.

21. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb.Diath. Haemorrh 1965;13:516-530.

22. Griffin JH, Evatt B, Zimmerman TS et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-1373.

23. Schwartz, HP, Fisher M, Hopmeier P et al. Plasma protein S deficiency in familal thrombotic disease. Blood. 1984;64:1297-1300.

24. Giri TK, Yamazaki T, Sala N et al. Deficient APC‑ cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. Blood. 2000;96:523-531.

25. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.

26. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3’- untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.

27. Manderstedt E, Lind‑Halldén C, Halldén C et al. Classic thrombophilias and thrombotic risk among middle‑aged and older adults: a population‑based cohort study. J Am Heart Assoc. 2022;11(4): e023018. DOI: 10.1161/JAHA.121.023018.

28. Manolio TA:Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166-76.

29. Bezemer ID, Bare LA, Doggen CJ et al. Gene variants associated with deep vein thrombosis. JAMA 2008; 299:1306-1314.

30. Trégouët DA, Heath S, Saut N et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009;113(21):5298-5303.

31. Tang W, Teichert M, Chasman DI et al. A genome‑wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Genet Epidemiol. 2013;37(5):512-521.

32. Lindström S, Wang L, Smith EN et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood. 2019;134 (19):1645-1657.

33. Klarin D, Busenkell E, Judy R et al. Genome‑wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet. 2019;51(11):1574-1579.

34. Zöller B, Svensson PJ, Dahlbäck B et al. Genetic risk factors for venous thromboembolism. Expert Rev Hematol. 2020;13(9):971-981.

35. Vrtel P, Slavik L, Vodicka R et al. Detection of unknown and rare pathogenic variants in antithrombin, protein C and protein S deficiency using high‑throughput targeted sequencing. Diagnostics (Basel) 2022;12(5):1060. DOI: 10.3390 /diagnostics12051060.

36. de Haan HG, Bezemer ID, Doggen CJ et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood. 2012;120(3):656-663.

37. van Hylckama Vlieg A, Flinterman LE, Bare LA et al. Genetic variations associated with recurrent venous thrombosis. Circ Cardiovasc Genet. 2014;7(6):806-13.

38. Kolin DA, Kulm S, Elemento O. Prediction of primary venous thromboembolism based on clinical and genetic factors within the U.K. Biobank. Sci Rep. 2021;11(1):21340. Erratum in: Sci Rep. 2021;11(1):23364.

39. Clifton L, Collister JA, Liu X et al. Assessing agreement between different polygenic risk scores in the UK Biobank. Sci Rep. 2022;12(1):12812.

40. Choi SW, Mak TS, O‚Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759-2772.